Morote, JuanBorque-Fernando, ÁngelTriquell, MarinaCelma, AnnaRegis, LucasMast, RichardTorres, Inés deSemidey, María E.Abascal-Junquera, José MaríaServian, PolSantamaria, AnnaPlanas, JacquesEsteban, Luis M.Trilla, Enrique2022-10-142022-10-142022Morote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Mast R, et al. Comparative analysis of PSA density and an MRI-Based predictive model to improve the selection of candidates for prostate biopsy. Cancers (Basel). 2022 May 11; 14(10): 2374. DOI: 10.3390/cancers141023742072-6694http://hdl.handle.net/10230/54398This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880-0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774-0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy.application/pdfengCopyright © 2022 by Morote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Mast R. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/cancers14102374Clinically significant prostate cancerPredictive modelProstate-specific antigen densityinfo:eu-repo/semantics/openAccess